Cellular Genomics Inc., of Branford, Conn., appointed Udo Klein senior vice president of drug development.

Codexis Inc., of Redwood City, Calif., appointed Peter Ketelaar director of business development, Europe.

Corcept Therapeutics Inc., of Menlo Park, Calif., appointed James Harper to its board.

Corus Pharma Inc., of Seattle, appointed Dinu Sen chief commercial officer.

Gene Express Inc., of Toledo, Ohio, selected Wilson Sonsini Goodrich & Rosati as its corporate law firm.

Genetics Squared Inc., of Ann Arbor, Mich., formed a scientific advisory board that includes Richard Cote as chairman, and David Fry and Phillip Banks as members.

Immtech International Inc., of Vernon Hills, Ill., appointed Carol Olson vice president and chief medical officer.

Immunicon Corp., of Huntingdon Valley, Pa., appointed Byron Hewett chief operating officer and general manager, cancer products.

Immunomedics Inc., of Morris Plains, N.J., appointed Brian Markison to its board.

Integrated BioPharma Inc., of Hillside, N.J., appointed Geoffrey Schild to the science advisory board of its subsidiary InB Biotechnologies Inc.

Isolagen Inc., of Houston, appointed Robert Partridge vice president, global marketing and communications.

Kosan Biosciences Inc., of Hayward, Calif., appointed Linda Pullan vice president, business development.

La Jolla Pharmaceuticals Co., of San Diego, appointed Craig Smith to its board.

MultiCell Technologies Inc., of Warwick, R.I., appointed Richard Ulevitch to its scientific advisory board.

Neurome Inc., of La Jolla, Calif., appointed Michael Khoury and Joseph Wender to its board.

Neuromed Technologies Inc., of Vancouver, British Columbia, appointed Mark Corrigan to its board.

NGN Capital LLC in New York appointed Peter Johann general partner.

Performance Plants Inc., of Kingston, Ontario, appointed Peter Matthewman vice president, business development.